Abiomed
Published January 27, 2005
This is not an offer to buy or sell. This in not a solicitation of business. The following is for informational purposes only. I own the stock.
COMPANY DESCRIPTION
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS(R) 5000 Biventricular Support System and the AB5000(TM) Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. In September 2004, ABIOMED applied for initial FDA market approval for the AbioCor(R) Implantable Replacement Heart to treat a defined subset of irreversible end-stage heart failure patients under a Humanitarian Device Exemption.
The company has two very interesting products.
AB5000(TM) Circulatory Support System
ABIOMED, Inc. (Nasdaq: ABMD) a manufacturer of products for circulatory care and support, today provided a clinical update for the AB5000 Circulatory Support System. Formally launched in April 2004, outcomes have continued to improve as the system has gone into wider use. ABIOMED's ventricular assist devices, the AB5000 and the BVS(R) 5000, are the only devices approved for Bridge-to- Recovery treatment following AMI-cardiogenic shock (shock following a heart attack). The systems are also used to support the heart and allow for potential recovery following other acute events including post cardiotomy cardiogenic shock (shock following coronary bypass surgery), and viral myocarditis, a virus that attacks the heart.
Key facts on AB5000 usage and outcomes, based on ABIOMED's voluntary data registry:
* More than seventy percent of survivors have been able to go home with their own hearts. In addition, recovery of kidney function has allowed some heart patients to avoid planned kidney transplants.
* One in four patients have been transitioned from the BVS 5000 to the AB5000. This transition took place without re-opening the chest,
avoiding bleeding and other risks associated with additional surgery to change out to other devices.
* Mean duration of support on the AB5000 is three times longer than on the BVS5000, with many patients requiring support beyond 30 or 60 days and some beyond 90 days. In bench testing, the AB5000 Ventricle has operated nearly a year and is continuing.
My name is Robert T DeMarco and I am a caregiver by choice. For those of you unfamiliar with the term "caregiver" it means someone who is responsible for the care and well-being of another, in my case, my 90-year-old mother who has Alzheimer's. There are millions of caregivers spread across the world, and perhaps surprisingly, 41% of us are male. I have a series of blogs including The Alzheimer’s Reading Room Weblog , The CareGiver Weblog , and The Robert T DeMarco Weblog .
- Abiomed
- Published: January 27, 2005
- Type:
- Section: Culture
- Writer: All American Investor
- All American Investor's BC Writer page
- All American Investor's personal site
- Spread the Word
- Like this article?
- Email this
Save to del.icio.us
Comments on this articleComments
This guy has polluted the site before. He uses it for MARKETING. It's cheap.
Go away, motherfucker.
Let's beat him at his own game: some numbers about this company:
EPS: -0.26
Moving Average Convergence/Divergence (MACD) indicates a Bearish Trend.
Chart pattern indicates a Strong Downward Trend.
Relative Strength is Bearish.
Up/Down volume pattern indicates that the stock is under Distribution.
The 50 day Moving Average is falling which is Bearish.
Zacks Rank for ABIOMED INC (ABMD):
[ 4 ] SELL Stocks with a Zacks Rank of 4 are considered a SELL and are the second lowest rating given by Zacks.
Here is a graph of the stock, showing the insider sales through the last year - note the pattern and lack of insider purchases.
Here is an interesting article about their attempts on avoiding publicity - a news blackout on their heart device
This does read exaclt like spam I get.
Is this a paid spot? Because that's what Blogads are for.
Aaman, I would agree with your technical analysis at this point in time. However, the black out on the mechanical heart is due to their application for the humanitarian device exception. The company announced sometime ago they were suspending testing of this device concurrent with their application.
The AB5000 business is growing fast and they have only gotten to about one percent of the addressable market.
As I stated clearly at the top of the post. This was intended for information only and I own the stock. A good investor looking for ideas could decide to investigate the story and then buy or short the stock. So you or anyone else is free to do as they see fit.
I am not a stockbroker nor do I work for the company. I do have an investor blog.
My real intention was to bring this story into the awareness of investors looking for ideas. This stock is not widely covered by research analyst at this time because the float is small and the volume is small. The Company did present at a Piper Jaffrey conference yesterday.
Nevertheless, the company has intriguing technology and a world class management team.
On the technical front you could have made the same comment when the stock dropped from the $14.00 area to the $8.50 area and you would have been correct for a time. But the methodolgy you described is more suited for short term trading from my point of view.
I feel the story behind this story is fundamental. Because both markets are enormous. But, that is my opinion on this one.
Perhaps we can come back to this post in a few months and discuss the price and the developments in the company at that time.
Meanwhile, I am open to new ideas on emerging companies if you have some. You never know where the next good investing idea is going to come from or who is going to supply the idea.
I am sorry I offended Shark. Please feel free to ignore me. Nevertheless, its OK by me if you prefer to spit venom.
Bob
Robert, thank you for your comments. I myself am a long term investor, but prefer to play it safe by only investing in "Foolish Four" type stocks and Type 1 stocks. This does not fit the bill - yet. Like I mentioned, interesting product.
Add your comment, speak your mind
(Or ping: http://blogcritics.org/mt/tb/24774)
This is an advert - not really a blogpost. Interesting product, though.